Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 175

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 175
---
-made) porphyrin molecule whose chemical name is meso-tetra (4-carboxyphenyl)                              
 porphine.                                                                                                                               |
| Transfection            |     | A                                                                                                                                       
 laboratory technique that is used to insert foreign nucleic acid (DNA or RNA) into a cell, typically with the intention of producing    
 a specific protein within the cell.                                                                                                     |
| Vitamin B12             |     | An                                                                                                                                      
 essential dietary nutrient that the body needs daily in small amounts to function and stay healthy. Vitamin B12 helps make red blood    
 cells, DNA, RNA, energy, and tissues, and keeps nerve cells healthy. It is found in liver, meat, eggs, poultry, shellfish, milk,        
 and milk products. Chronic lack of vitamin B12 can result in anemia and central nervous system problems.                                |

| 99 |

<div align='center'>INDEX TO FINANCIAL STATEMENTS

bioAffinity Technologies, Inc.

Index to the Condensed Consolidated Financial Statements (unaudited)</div>

| Condensed Consolidated                                                                
 Balance Sheets at March 31, 2025 (unaudited) and December 31, 2024                    
 Unaudited Condensed Consolidated                                                      
 Statements of Operations for the Three Months ended March 31, 2025 and 2024           | F-2 
 F-3 |
|:--------------------------------------------------------------------------------------|:----|
| Unaudited Condensed Consolidated                                                      
 Statements of Stockholders’ Equity for the Three Months ended March 31, 2025 and 2024 | F-4 |
| Unaudited Condensed Consolidated                                                      
 Statements of Cash Flows for the Three Months ended March 31, 2025 and 2024           | F-5 |
| Notes to Unaudited Condensed                                                          
 Consolidated Financial Statements                                                     | F-6 |

<div align='center'>Index to the Consolidated Financial Statements</div>

| Report of Independent Registered Public Accounting Firm (PCAOB ID NO. 100)                                                                
 Consolidated Balance Sheets as of December 31, 2024 and 2023                                                                              
 Consolidated Statements of Operations for the years ended December 31, 2024 and 2023                                                      | F-15 
 F-16 
 F-17 |
|:------------------------------------------------------------------------------------------------------------------------------------------|:-----|
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity for the years ended December 31, 2024 and 202